What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

Identify therapeutic vulnerabilities in diffuse midline glioma and develop multimodal treatment strategies.

November 1, 2025Neuro-OncologyOpen Access

EXTH-83. Exploiting Cell-of-Origin Vulnerabilities to Guide Multimodal Strategies in Diffuse Midline Glioma

View Full Paper

Ask AI

Bookmark

Authors

MDMatthew Dun EJEvangeline Jackson IFIzac Findlay

Discussion

Member takes

Implication

CRISPR screens reveal hyperglycemia influences treatment efficacy in glioma, suggesting metformin with immune checkpoint inhibitors may enhance survival.

Key Points

Identify therapeutic vulnerabilities in diffuse midline glioma and develop multimodal treatment strategies.
Conducted CRISPR-Cas9 loss-of-function screens across 38 patient-derived models
Combined PI3K/mTOR inhibitors with metformin to manage hyperglycemia
Examined phosphoproteomic changes and immune modulation in treatment models
Identified hyperglycemia and hyperinsulinemia as issues with systemic PI3K inhibition
Showed metformin restored glucose balance and enhanced treatment effects
Demonstrated that treatment regimens sensitized tumors to immune checkpoint inhibitors, promoting long-term survival

Cite This Study

Dun et al. (2025) studied this question.

synapsesocial.com/papers/69254366c0ce034ddc35846d https://doi.org/10.1093/neuonc/noaf201.1416

View Full Paper

Ask AI

Bookmark

Implication

CRISPR screens reveal hyperglycemia influences treatment efficacy in glioma, suggesting metformin with immune checkpoint inhibitors may enhance survival.

EXTH-83. Exploiting Cell-of-Origin Vulnerabilities to Guide Multimodal Strategies in Diffuse Midline Glioma

Discussion

Member takes

Implication

Key Points

Cite This Study

EXTH-83. Exploiting Cell-of-Origin Vulnerabilities to Guide Multimodal Strategies in Diffuse Midline Glioma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider